retatrutide side effects trial results VisualAbstract: reduces body weight by 17.5% in patients with obesity 🚨The first phase 3 retatrutide

People with a History of Certain Cancers : Specifically, those with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

In obese subjects without diabetes, SGLT2 inhibitors do not alter the estimated glomerular filtration rate or have any adverse event potentially related to renal impairment or renal failure over a 52-week period [21]

Understanding the regulatory process For researchers less familiar with pharmaceutical regulation, a brief overview of the FDA approval process helps contextualize where retatrutide stands and what comes next

Report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia, or dyspnea) to your healthcare provider